2020 journal article

Atenolol in cats with subclinical hypertrophic cardiomyopathy: a double-blind, placebo-controlled, randomized clinical trial of effect on quality of life, activity, and cardiac biomarkers


By: A. Coleman n, T. DeFrancesco n, E. Griffiths n, B. Lascelles n, D. Kleisch n, C. Atkins n, B. Keene n

author keywords: Feline; Beta-btocker; Accelerometry
MeSH headings : Administration, Oral; Animals; Anti-Arrhythmia Agents / administration & dosage; Anti-Arrhythmia Agents / therapeutic use; Atenolol / administration & dosage; Atenolol / therapeutic use; Biomarkers / blood; Cardiomyopathy, Hypertrophic / drug therapy; Cardiomyopathy, Hypertrophic / veterinary; Cat Diseases / blood; Cat Diseases / drug therapy; Cats; Double-Blind Method; Female; Male; Quality of Life; Treatment Outcome
TL;DR: This study failed to identify an effect of subclinical HCM on owner-assessed QOL or activity or a treatment effect of atenolol on these variables at the dosage evaluated, and these findings do not support a treatment benefit of atanolol for the goal of symptom reduction in cats with sub clinical HCM. (via Semantic Scholar)
UN Sustainable Development Goal Categories
Sources: Web Of Science, NC State University Libraries, ORCID
Added: September 21, 2020

Citation Index includes data from a number of different sources. If you have questions about the sources of data in the Citation Index or need a set of data which is free to re-distribute, please contact us.

Certain data included herein are derived from the Web of Science© and InCites© (2024) of Clarivate Analytics. All rights reserved. You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.